Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
55 hedge funds and large institutions have $204M invested in Intra-Cellular Therapies Inc. in 2014 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 8 closing their positions.
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
129% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 7
57% more funds holding
Funds holding: 35 → 55 (+20)
2% more capital invested
Capital invested by funds: $201M → $204M (+$3.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.97M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.59M |
| 4 |
Morgan Stanley
New York
|
+$1.96M |
| 5 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$4.08M |
| 2 |
DM
Deerfield Management
New York
|
-$3.12M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$1.48M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.14M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$487K |
ITCI Hedge Fund Activity: Q2 2014 in Review
55 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2014, worth a combined $204M — up 1.6% from $201M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ITCI positions and 8 closed out — a net gain of 21 holders — while 16 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $6.97M. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.08M sold.
- 55 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2014, up from 35 in Q1 2014.
- Funds reported $204M of Intra-Cellular Therapies Inc. stock for Q2 2014, up 1.6% quarter-over-quarter.
- 29 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2014 and 8 closed out, a net change of +21 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $6.97M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2014 was Broadfin Capital, an estimated $4.08M sold.
Based on aggregated 13F filings for Q2 2014.